Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Myelodysplastic Syndromes 4Leukemia, Lymphocytic, Chronic, B-Cell 4Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Hairy Cell 2Hodgkin Disease 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Sarcoma, Myeloid 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Cyclophosphamide 4Prednisone 3Lenalidomide 3fludarabine phosphate 2etoposide phosphate 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Stem Cell Transplantation 2Nivolumab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Doxorubicin 2Bortezomib 2Alemtuzumab 2tazemetostat 1sargramostim 1romidepsin 1poly ICLC 1plerixafor 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1pegaspargase 1liposomal doxorubicin 1forodesine 1fludarabine 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell × plerixafor × Clear all
NCT01746173 2023-01-30

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Terminated
5 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡